leuprorelin + tamoxifen

Leuprorelin + tamoxifen is a combination therapy used primarily in the adjuvant treatment of hormone receptor-positive early-stage breast cancer in premenopausal women. Leuprorelin is a luteinizing hormone-releasing hormone (LHRH) agonist that suppresses ovarian estrogen production by downregulating pituitary gonadotropins, leading to medical ovarian suppression. Tamoxifen is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to its receptor on breast cancer cells, thereby blocking the proliferative action of estrogen. The combination aims to maximize endocrine suppression and reduce recurrence risk in high-risk premenopausal patients[2][3][5][7]. This regimen is typically administered after surgery for early-stage disease and may be given for several years as part of adjuvant therapy.

Brand names

Prostap DCS (for leuprorelin component)Leuplin (for leuprorelin component)

Other names

leuprolide + tamoxifenleuprorelin acetate + tamoxifen